Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)

EDUARDO MUÑOZ BLANCO2026-01-292026-01-29201710.1016/j.phrs.2017.04.0022-s2.0-85018561888https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/28062PharmacologyCorrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)corrigendum